Drug Database
Back to search

Poland· PL-100303157

Giotrif

A afatinib product containing afatinibum, registered in Poland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC L01EB03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGiotrifATCL01EB03REGISTER NO.PL-100303157PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about afatinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Afatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EB03 (afatinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search afatinib products by name

Afatinib · ATC L01EB03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of afatinib costs, country by country.

Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Afatinib · price per daily dose (40 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$199.66
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Afatinibum
Manufacturer
Boehringer Ingelheim International GmbH
Country
Poland (PL)
ATC code
L01EB03
ATC class
Afatinib
Defined daily dose
40 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909991602529
  • gtin
    05909991083373
  • gtin
    05909991083380
  • gtin
    05909991083397

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

170 interactions on record for afatinib.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check afatinib against other medicinesHow interaction checks work

Afatinib · interactions on record

170 records

  • 10 severe
  • 158 moderate
  • 2 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • Aminolevulinic acidL01XD04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Afatinib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All afatinib products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Cyprus · Afatinib Afatinib, Afatinib Sapiens
  • Greece · Webrix
  • Iceland · Giotrif
  • Liechtenstein · Giotrif
  • Latvia · Afatinib, Afatinib Lotus
  • Malta · Afatinib Lotus
  • Norway · Giotrif
  • Sweden · Afatinib Lotus, Webrix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b53f8520-c7c1-456e-9c8d-8303a2ec0863
GET /v1/drugs/b53f8520-c7c1-456e-9c8d-8303a2ec0863?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "20 mg",
  "packaging": "05909991083373 ¦ Rpz ¦ EU/1/13/879/001 ¦ 86327\n7 tabl.\n05909991083380 ¦ Rpz ¦ EU/1/13/879/002 ¦ 86328\n14 tabl.\n05909991083397 ¦ Rpz ¦ EU/1/13/879/003 ¦ 86329\n28 tabl.\n05909991602529 ¦ Rpz ¦ EU/1/13/879/013 ¦ 167265\n1 butelka 30 tabl.",
  "substance": null,
  "common_name": "Afatinibum",
  "pl_product_id": "100303157",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about afatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console